Alectinib in Neo-adjuvant Treatment of Stage III NSCLC
Status:
Recruiting
Trial end date:
2026-05-28
Target enrollment:
Participant gender:
Summary
Stage III NSCLC is a heterogeneous group of tumors with a wide spectrum of clinical
presentations. Across this wide spectrum of heterogeneity, there is no single deļ¬nitive
therapeutic approach and the definition of the most effective treatment approach needs a
multidisciplinary approach. In this trial we want to test in ALK positive stage III locally
advanced NSCLC patients, the efficacy of Alectinib to induce tumor shrinkage when
administered before surgery and to reduce the possibility of disease recurrence, with a
limited risk of toxicity related, in long term administration after surgery.